Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014:2014:143426.
doi: 10.1155/2014/143426. Epub 2014 Aug 24.

Anti-VEGF Cancer Therapy in Nephrology Practice

Hassan Izzedine  1
Affiliations
Review

Anti-VEGF Cancer Therapy in Nephrology Practice

Hassan Izzedine. Int J Nephrol. 2014.

Abstract

Expanded clinical experience with the antivascular endothelial growth factor (VEGF) agents has come with increasing recognition of their renal adverse effects. Although renal histology is rarely sought in antiangiogenic-treated cancer patients, kidney damage related to anti-VEGF is now established. Its manifestations include hypertension, proteinuria, and mainly glomerular thrombotic microangiopathy. Then, in nephrology practice, should we continue to perform kidney biopsy, and what should be done with the anti-VEGF agents in case of renal toxicity?

PubMed Disclaimer

Figures

Figure 1
Figure 1
Potential mechanisms of hypertension related to anti-VEGF agents.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Dvorak HF. Angiogenesis: update 2005. Journal of Thrombosis and Haemostasis. 2005;3(8):1835–1842. - PubMed
    1. Bhadada SV, Goyal BR, Patel MM. Angiogenic targets for potential disorders. Fundamental and Clinical Pharmacology. 2011;25(1):29–47. - PubMed
    1. Müller-Deile J, Worthmann K, Saleem M, Tossidou I, Haller H, Schiffer M. The balance of autocrine VEGF-A and VEGF-C determines podocyte survival. American Journal of Physiology-Renal Physiology. 2009;297(6):F1656–F1667. - PubMed
    1. Izzedine H, Massard C, Spano JP, Goldwasser F, Khayat D, Soria JC. VEGF signalling inhibition-induced proteinuria: mechanisms, significance and management. European Journal of Cancer. 2010;46(2):439–448. - PubMed
    1. Barakat RK, Singh N, Lal R, Verani RR, Finkel KW, Foringer JR. Interstitial nephritis secondary to bevacizumab treatment in metastatic leiomyosarcoma. Annals of Pharmacotherapy. 2007;41(4):707–710. - PubMed

LinkOut - more resources